Please assess the completion status of the following clinical trial:

Trial Title: HIGH Altitude CArdiovascular REsearch in the ANDES

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Permanent residence at low (\<500 m) altitude~* Conventional systolic BP (average of two measurements) 140-159 mmHg or conventional diastolic BP 90-99 mmHg in subjects untreated or after 4 weeks of washout~* Mean daytime systolic BP ≥135 and \<150 mmHg and/or mean daytime diastolic BP ≥85 and \<95 mmHg in subjects untreated or after 4 weeks of washout~* Written informed consent to participate in the study~Exclusion Criteria:~* Conventional systolic BP (average of two measurements) ≥150 mmHg and conventional diastolic BP ≥95 mmHg in treated subjects~* Regular use of two or more antihypertensive drugs (with the exception of subjects on two antihypertensive drugs in low doses)~* Treated antihypertensive subjects in whom withdrawal of treatment is deemed unethical by the investigator (e.g. because of the existence of compelling indications other than hypertension for continuous use of previously used antihypertensive agent)~* Contraindications (including a history of adverse reactions) to angiotensin receptor blockers or calcium antagonists~* History of serious mountain sickness~* Subjects who over 3 months preceding inclusion in the study spent considerable (\> 1 week) amount of time at altitudes above 2500 m.~* Cardiovascular diseases other than hypertension (coronary heart disease, heart failure, atrial fibrillation, valvular or congenital heart disease, cardiomyopathies, cerebrovascular disease, peripheral artery disease, aortic aneurysm)~* Suspected or confirmed secondary hypertension~* Diabetes mellitus~* Serious respiratory disorders~* Other conditions deemed relevant by the investigator (including liver disease, renal disease, thyroid disorders)~* BMI ≥35 kg/m2~* Upper arm circumference \>32 cm~* known severe obstructive sleep apnea (apnea-hypopnea index \> 30 or use of CPAP) or excessive daytime sleepiness (Epworth Sleepiness Scale \> 10)~* Pregnancy~* Premenopausal women not using effective contraceptive methods~* Elevated probability of noncompliance with the study procedures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Telmisartan/nifedipine (Type: EXPERIMENTAL): Subjects treated with telmisartan 80 mg (1 capsule daily in the morning) plus nifedipine slow release 30 mg (1 capsule daily in the morning) combination
- Placebo (Type: PLACEBO_COMPARATOR): Two tablets containing placebo daily in the morning

Based on this trial design, predict the completion outcome and termination type (if applicable).